Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's disease
- 19 July 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (32), 5280-5287
- https://doi.org/10.1016/j.vaccine.2010.05.054
Abstract
No abstract availableFunding Information
- UTSouthwestern Alzheimer's Disease Center (P30AG12300-16)
- Rudman Foundation
- Alzheimer's Association Research (IIRG-06-24428)
This publication has 47 references indexed in Scilit:
- DNA prime–protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type miceGene Therapy, 2009
- DNA β-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse ModelJAMA, 2009
- DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotypeJournal of Neuroimmunology, 2008
- Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic StrategyPLOS ONE, 2008
- NADP Regulates the Yeast GAL Induction SystemScience, 2008
- The GAL4 SystemMethods in molecular biology (Clifton, N.J.), 2008
- Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric Aβ Species in Amyloid Precursor Protein Transgenic MiceJournal of Neuroscience, 2007
- Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic miceJournal of the Neurological Sciences, 2007
- Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's diseaseImmunology Letters, 2007
- Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Aβ1‐6 upregulates IL‐10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's diseaseThe Journal of Gene Medicine, 2007